Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 16 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Finasteride and Tadalafil Capsules. The company is the first approved applicant for these capsules and will benefit from a period of exclusivity. The drug is intended for the treatment of benign prostatic hyperplasia and will be manufactured in Ahmedabad. This filing serves to inform investors and the exchange about this significant regulatory approval.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 16, 2024, titled "Zydus receives final approval from USFDA and 180 days CGT exclusivity for Finasteride and Tadalafil Cap Capsules".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases